These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 27806325)

  • 1. Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
    Matre P; Velez J; Jacamo R; Qi Y; Su X; Cai T; Chan SM; Lodi A; Sweeney SR; Ma H; Davis RE; Baran N; Haferlach T; Su X; Flores ER; Gonzalez D; Konoplev S; Samudio I; DiNardo C; Majeti R; Schimmer AD; Li W; Wang T; Tiziani S; Konopleva M
    Oncotarget; 2016 Nov; 7(48):79722-79735. PubMed ID: 27806325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition.
    Jacque N; Ronchetti AM; Larrue C; Meunier G; Birsen R; Willems L; Saland E; Decroocq J; Maciel TT; Lambert M; Poulain L; Hospital MA; Sujobert P; Joseph L; Chapuis N; Lacombe C; Moura IC; Demo S; Sarry JE; Recher C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2015 Sep; 126(11):1346-56. PubMed ID: 26186940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.
    Emadi A; Jun SA; Tsukamoto T; Fathi AT; Minden MD; Dang CV
    Exp Hematol; 2014 Apr; 42(4):247-51. PubMed ID: 24333121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
    Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of the interactions of potent allosteric inhibitors with glutaminase C, a key enzyme in cancer cell glutamine metabolism.
    Huang Q; Stalnecker C; Zhang C; McDermott LA; Iyer P; O'Neill J; Reimer S; Cerione RA; Katt WP
    J Biol Chem; 2018 Mar; 293(10):3535-3545. PubMed ID: 29317493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia.
    Gregory MA; Nemkov T; Reisz JA; Zaberezhnyy V; Hansen KC; D'Alessandro A; DeGregori J
    Exp Hematol; 2018 Feb; 58():52-58. PubMed ID: 28947392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targeting of glutaminase sensitizes ovarian cancer cells to chemotherapy.
    Masamha CP; LaFontaine P
    J Cell Biochem; 2018 Jul; 119(7):6136-6145. PubMed ID: 29633308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glutamine metabolism via glutaminase 1 in autosomal-dominant polycystic kidney disease.
    Soomro I; Sun Y; Li Z; Diggs L; Hatzivassiliou G; Thomas AG; Rais R; Parker SJ; Slusher BS; Kimmelman AC; Somlo S; Skolnik EY
    Nephrol Dial Transplant; 2018 Aug; 33(8):1343-1353. PubMed ID: 29420817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer.
    Gross MI; Demo SD; Dennison JB; Chen L; Chernov-Rogan T; Goyal B; Janes JR; Laidig GJ; Lewis ER; Li J; Mackinnon AL; Parlati F; Rodriguez ML; Shwonek PJ; Sjogren EB; Stanton TF; Wang T; Yang J; Zhao F; Bennett MK
    Mol Cancer Ther; 2014 Apr; 13(4):890-901. PubMed ID: 24523301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of a novel glutaminase inhibitor.
    Cederkvist H; Kolan SS; Wik JA; Sener Z; Skålhegg BS
    FEBS Open Bio; 2022 Jan; 12(1):163-174. PubMed ID: 34698439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glutaminase-1 stimulates the proliferation, migration, and survival of human endothelial cells.
    Peyton KJ; Liu XM; Yu Y; Yates B; Behnammanesh G; Durante W
    Biochem Pharmacol; 2018 Oct; 156():204-214. PubMed ID: 30144404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutaminase 1 regulates the release of extracellular vesicles during neuroinflammation through key metabolic intermediate alpha-ketoglutarate.
    Wu B; Liu J; Zhao R; Li Y; Peer J; Braun AL; Zhao L; Wang Y; Tong Z; Huang Y; Zheng JC
    J Neuroinflammation; 2018 Mar; 15(1):79. PubMed ID: 29540215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).
    Robinson MM; McBryant SJ; Tsukamoto T; Rojas C; Ferraris DV; Hamilton SK; Hansen JC; Curthoys NP
    Biochem J; 2007 Sep; 406(3):407-14. PubMed ID: 17581113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The activation loop and substrate-binding cleft of glutaminase C are allosterically coupled.
    Li Y; Ramachandran S; Nguyen TT; Stalnecker CA; Cerione RA; Erickson JW
    J Biol Chem; 2020 Jan; 295(5):1328-1337. PubMed ID: 31871054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational changes in the activation loop of mitochondrial glutaminase C: A direct fluorescence readout that distinguishes the binding of allosteric inhibitors from activators.
    Stalnecker CA; Erickson JW; Cerione RA
    J Biol Chem; 2017 Apr; 292(15):6095-6107. PubMed ID: 28196863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.
    Shukla K; Ferraris DV; Thomas AG; Stathis M; Duvall B; Delahanty G; Alt J; Rais R; Rojas C; Gao P; Xiang Y; Dang CV; Slusher BS; Tsukamoto T
    J Med Chem; 2012 Dec; 55(23):10551-63. PubMed ID: 23151085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting glutamine metabolism slows soft tissue sarcoma growth.
    Lee P; Malik D; Perkons N; Huangyang P; Khare S; Rhoades S; Gong YY; Burrows M; Finan JM; Nissim I; Gade TPF; Weljie AM; Simon MC
    Nat Commun; 2020 Jan; 11(1):498. PubMed ID: 31980651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the molecular mechanisms of glutaminase C inhibitors in cancer cells using serial room temperature crystallography.
    Milano SK; Huang Q; Nguyen TT; Ramachandran S; Finke A; Kriksunov I; Schuller DJ; Szebenyi DM; Arenholz E; McDermott LA; Sukumar N; Cerione RA; Katt WP
    J Biol Chem; 2022 Feb; 298(2):101535. PubMed ID: 34954143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. All-Trans Retinoic Acid Synergizes with Enasidenib to Induce Differentiation of IDH2-Mutant Acute Myeloid Leukemia Cells.
    Kim Y; Jeung HK; Cheong JW; Song J; Bae SH; Lee JI; Min YH
    Yonsei Med J; 2020 Sep; 61(9):762-773. PubMed ID: 32882760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and evaluation of novel glutaminase inhibitors.
    McDermott LA; Iyer P; Vernetti L; Rimer S; Sun J; Boby M; Yang T; Fioravanti M; O'Neill J; Wang L; Drakes D; Katt W; Huang Q; Cerione R
    Bioorg Med Chem; 2016 Apr; 24(8):1819-39. PubMed ID: 26988803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.